CLINICAL TRIALS PROFILE FOR PROGLYCEM
✉ Email this page to a colleague
All Clinical Trials for PROGLYCEM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00892073 ↗ | Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy | Completed | The Hospital for Sick Children | Phase 2 | 2006-05-01 | To study the effect of combined diazoxide-metformin therapy on body weight in youth with hypothalamic obesity following treatment for craniopharyngioma. A secondary objective is to evaluate changes in insulin resistance (IR), beta-cell function, features of the metabolic syndrome, muscle metabolism and intramyocellular lipid. Hypothesis: Treatment with diazoxide and metformin will result in weight loss or slowed weight gain and improved metabolic profile, compared to pretreatment levels. |
| NCT00987168 ↗ | Sandostatine® LP and Hyperinsulinism | Completed | Novartis | Phase 2 | 2009-05-01 | To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism. |
| NCT00987168 ↗ | Sandostatine® LP and Hyperinsulinism | Completed | Assistance Publique - Hôpitaux de Paris | Phase 2 | 2009-05-01 | To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism. |
| NCT03540758 ↗ | Regulation of Endogenous Glucose Production by Central KATP Channels | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2018-08-01 | Type 2 diabetes affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROGLYCEM
Condition Name
Clinical Trial Locations for PROGLYCEM
Trials by Country
Clinical Trial Progress for PROGLYCEM
Clinical Trial Phase
Clinical Trial Sponsors for PROGLYCEM
Sponsor Name
| Sponsor Name for PROGLYCEM | |
| Sponsor | Trials |
| Albert Einstein College of Medicine | 3 |
| Albert Einstein College of Medicine, Inc. | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
